Cardiovascular calcification and atherosclerosis accelerated during uremia;Calcificazioni cardiovascolari e aterosclerosi accelerata in corso di uremia

Italian Heart Journal Supplement

Volumn 6, Issue 1, 2005, Pages 25-28

  Cozzolino, Mario ^a   Butti, Alessandra ^a   Chiarelli, Giusy ^a   Rocca Rey, Lisa ^a   Santagostino, Gaia ^a   Gallieni, Maurizio ^a   Brancaccio, Diego ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Calcification; Calcium; Kidney; Phosphates

Indexed keywords

CALCITRIOL; CALCIUM; PHOSPHATE BINDING AGENT; CALCIUM CHANNEL STIMULATING AGENT; CHELATING AGENT; PHOSPHATE; PHOSPHATE BINDING PROTEIN;

ATHEROSCLEROSIS; CALCIFICATION; CALCIUM BLOOD LEVEL; DIALYSIS; HUMAN; HYPERPARATHYROIDISM; HYPERPHOSPHATEMIA; IN VITRO STUDY; PHOSPHATE BLOOD LEVEL; REVIEW; SMOOTH MUSCLE FIBER; UREMIA; ANIMAL; ARTERIOSCLEROSIS; BLOOD; CALCINOSIS; CARDIOVASCULAR DISEASE; CELL CULTURE; CHRONIC KIDNEY FAILURE; COMPARATIVE STUDY; MOUSE; MOUSE MUTANT; RENAL REPLACEMENT THERAPY; RISK FACTOR; SECONDARY HYPERPARATHYROIDISM;

ANIMALS; ARTERIOSCLEROSIS; CALCINOSIS; CALCITRIOL; CALCIUM CHANNEL AGONISTS; CARDIOVASCULAR DISEASES; CELLS, CULTURED; CHELATING AGENTS; HUMANS; HYPERPARATHYROIDISM, SECONDARY; KIDNEY FAILURE, CHRONIC; MICE; MICE, KNOCKOUT; PHOSPHATE-BINDING PROTEINS; PHOSPHATES; RENAL DIALYSIS; RISK FACTORS; UREMIA;

EID: 15944386326     PISSN: 11294728     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (33)

1. 4 product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol 2001; 12: 2131-8.
2. Block GA, Hulbert-Shearon TE, Levin NW, Port FK. Association of serum phosphorus and calcium X phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 1998, 31: 607-17.
3. European Transplantation and Dialysis Association. Report on management of renal failure in Europe, XXIV, 1993. Nephrol Dial Transplant 1995; 10 (Suppl 5): 12.
4. US Renal Data System: causes of death. Annual data report. Bethesda, MD: National Institute of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 1995; 14: 79-90.
5. Goodman WG, Goldin J, Kuizon BD, et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2000; 342: 1478-83.
6. London GM, Pannier B, Marchais SJ, Guerin AP. Calcification of the aortic valve in the dialyzed patient. J Am Soc Nephrol 2000; 11: 778-83.
7. Jakoby MG 4th, Semenkovich CF. The role of osteoprogenitors in vascular calcification. Curr Opin Nephrol Hypertens 2000; 9: 11-5.
8. Cozzolino M, Dusso A, Slatopolsky E. Role of calcium X phosphate product and bone associated proteins on vascular calcification in renal failure. J Am Soc Nephrol 2001; 12: 2511-6.
9. Christian RC, Fitzpatrick LA. Vascular calcification. Curr Opin Nephrol Hypertens 1999; 8: 443-8.
10. Cozzolino M, Brancaccio D, Gallieni M, Slatopolsky E. Pathogenesis of vascular calcification in chronic kidney disease. Kidney Int 2005, in press.
11. Luo G, Ducy P, McKee MD, et al. Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein. Nature 1997; 386: 78-81.
12. Shearer MJ. Role of vitamin K and gla proteins in the patho-physiology of osteoporosis and vascular calcification. Curr Opin Clin Nutr Metab Care 2000; 3: 433-8.
13. Jono S, Ikari Y, Vermeer C, et al. Matrix Gla protein is associated with coronary artery calcification assessed by electron-beam computed tomography. Thromb Haemost 2004; 91: 790-4.
14. Schinke T, Amendt C, Trindl A, et al. The serum protein α2-HS glycoprotein/fetuin inhibits apatite formation in vitro and in mineralizing calvaria cells. A possible role in mineralization and calcium homeostasis. J Biol Chem 1996; 271: 20789-96.
15. Schafer C, Heiss A, Schwarz A, et al. The serum protein α2-Heremans-Schmid glycoprotein/fetuin-A is a systemically acting inhibitor of ectopic calcification. J Clin Invest 2003; 112: 357-66.
16. Ketteler M, Bongartz P, Westenfeld R, et al. Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: a cross-sectional study. Lancet 2003; 361: 827-33.
17. Jono S, McKee MD, Murry CE, et al. Phosphate regulation of vascular smooth muscle cell calcification. Circ Res 2000; 87: E10-E17.
18. Giachelli CM. Vascular calcification: in vitro evidence for the role of inorganic phosphate. J Am Soc Nephrol 2003; 14 (Suppl): S300-S304.
19. Ducy P, Zhang R, Geoffroy V, et al. Osf2/Cbfa1: a transcriptional activator of osteoblast differentiation. Cell 1997; 89: 747-54.
20. Kuro-o M, Matsumura Y, Aizawa H, et al. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature 1997; 390: 45-51.
21. Ibels LS, Alfrey AC, Haut L, Huffer WE. Preservation of function in experimental renal disease by dietary restriction of phosphate. N Engl J Med 1978; 298: 122-6.
22. Gimenez LF, Solez K, Walker WG. Relation between renal calcium content and renal impairment in 246 human renal biopsies. Kidney Int 1987; 31: 93-9.
23. Nagano N, Miyata S, Obana S, et al. Sevelamer hydrochloride, a phosphate binder, protects against deterioration of renal function in rats with progressive chronic renal insufficiency. Nephrol Dial Transplant 2003; 16: 2014-23.
24. Cozzolino M, Dusso AS, Liapis H, et al. The effects of sevelamerhydro chloride and calcium carbonate on kidney calcification in uremic rats. J Am Soc Nephrol 2002; 13: 2299-308.
25. Katsumata K, Kusano K, Hirata M, et al. Sevelamer hydrochloride prevents ectopic calcification and renal osteodystrophy in chronic renal failure rats. Kidney Int 2003; 64: 441-50.
26. Cozzolino M, Staniforth ME, Liapis H, et al. Sevelamer hydro chloride attenuates kidney and cardiovascular calcifications in long-term experimental uremia. Kidney Int 2003; 64: 1653-61.
27. Hsu CH. Are we mismanaging calcium and phosphate metabolism in renal failure? Am J Kidney Dis 1997; 29: 641-9.
28. Brancaccio D, Tetta C, Gallieni M, Panichi V. Inflammation, CRP, calcium overload and a high calcium-phosphate product: a "liaison dangereuse". Nephrol Dial Transplant 2002; 17: 201-3.
29. Walser M. Calcium carbonate-induced effects on serum Ca × P product and serum creatinine in renal failure: a retrospective study. Adv Exp Med Biol 1980; 128: 281-7.
30. Chertow GM, Burke SK, Lazarus JM, et al. Poly[allylamine hydrochloride] (RenaGel): a noncalcemic phosphate binder for the treatment of hyperphosphatemia in chronic renal failure. Am J Kidney Dis 1997; 29: 66-71.
31. Chertow GM, Burke SK, Dillon MA, Slatopolsky E. Long-term effects of sevelamer hydrochloride on the calcium × phosphate product and lipid profile of haemodialysis patients. Nephrol Dial Transplant 1999; 12: 2907-14.
32. Bleyer AJ, Burke SK, Dillon M, et al. A comparison of the calcium-free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients. Am J Kidney Dis 1999; 33: 694-701.
33. Chertow GM, Burke SK, Raggi R et al. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 2002; 62: 245-52.